Kilitch Drugs (India) Ltd
₹ 470
-0.13%
21 May
4:01 p.m.
About
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
Key Points
- Market Cap ₹ 756 Cr.
- Current Price ₹ 470
- High / Low ₹ 486 / 271
- Stock P/E 24.3
- Book Value ₹ 157
- Dividend Yield 0.00 %
- ROCE 15.4 %
- ROE 13.1 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 60.7% CAGR over last 5 years
- Company's median sales growth is 15.1% of last 10 years
Cons
- Stock is trading at 2.94 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 9.90% over last 3 years.
- Earnings include an other income of Rs.13.7 Cr.
- Company has high debtors of 168 days.
- Working capital days have increased from 127 days to 199 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | 19 | 21 | 27 | 50 | 96 | 61 | 70 | 105 | 118 | 132 | 182 | |
| 19 | 21 | 24 | 27 | 44 | 79 | 59 | 65 | 94 | 100 | 111 | 151 | |
| Operating Profit | -4 | -2 | -3 | -0 | 6 | 17 | 2 | 5 | 11 | 17 | 20 | 31 |
| OPM % | -25% | -9% | -15% | -0% | 12% | 18% | 3% | 8% | 11% | 15% | 16% | 17% |
| 6 | 3 | 2 | 1 | 3 | 4 | 6 | 4 | 5 | 5 | 6 | 14 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 1 | -1 | -2 | -0 | 7 | 20 | 5 | 8 | 14 | 19 | 23 | 41 |
| Tax % | -10% | -79% | -18% | -91% | 13% | 24% | 15% | 18% | 24% | 19% | 25% | 23% |
| 1 | -0 | -2 | -0 | 6 | 15 | 4 | 6 | 11 | 16 | 18 | 31 | |
| EPS in Rs | 0.89 | -0.14 | -1.55 | -0.03 | 4.52 | 9.62 | 2.89 | 3.98 | 6.76 | 10.09 | 10.93 | 19.38 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% | 5% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 48% |
| 5 Years: | 61% |
| 3 Years: | 48% |
| TTM: | 86% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 39% |
| 3 Years: | 44% |
| 1 Year: | 37% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 107 | 107 | 105 | 106 | 117 | 136 | 136 | 147 | 162 | 180 | 207 | 237 |
| 0 | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 31 | 49 | |
| 9 | 7 | 8 | 10 | 13 | 12 | 10 | 18 | 34 | 35 | 33 | 56 | |
| Total Liabilities | 129 | 127 | 126 | 130 | 145 | 172 | 174 | 196 | 232 | 252 | 287 | 358 |
| 9 | 9 | 8 | 8 | 7 | 8 | 8 | 7 | 14 | 15 | 16 | 20 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 47 |
| Investments | 40 | 72 | 92 | 96 | 101 | 100 | 98 | 106 | 117 | 110 | 121 | 121 |
| 79 | 46 | 25 | 26 | 37 | 65 | 68 | 82 | 101 | 126 | 145 | 170 | |
| Total Assets | 129 | 127 | 126 | 130 | 145 | 172 | 174 | 196 | 232 | 252 | 287 | 358 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -31 | -8 | 18 | 1 | -1 | 7 | 7 | 6 | 5 | 6 | -11 | 15 | |
| 72 | -31 | -20 | -1 | -2 | -22 | -10 | -5 | -16 | 6 | -10 | -41 | |
| -0 | -0 | -0 | -0 | 6 | 15 | 1 | 2 | 8 | 3 | 11 | 16 | |
| Net Cash Flow | 41 | -39 | -2 | -0 | 2 | 0 | -1 | 3 | -3 | 15 | -10 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 213 | 243 | 285 | 200 | 150 | 88 | 102 | 120 | 144 | 165 | 171 | 168 |
| Inventory Days | 162 | 124 | 110 | 84 | 39 | 33 | 57 | 34 | 30 | 13 | 22 | 61 |
| Days Payable | 292 | 123 | 152 | 183 | 108 | 38 | 81 | 127 | 168 | 180 | 144 | 188 |
| Cash Conversion Cycle | 83 | 244 | 243 | 101 | 82 | 83 | 78 | 27 | 6 | -3 | 49 | 40 |
| Working Capital Days | 102 | 196 | 231 | 130 | 104 | 78 | 96 | 62 | 50 | 71 | 112 | 199 |
| ROCE % | -2% | -1% | -2% | -0% | 5% | 12% | 3% | 4% | 7% | 9% | 10% | 15% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1m - Newspaper Publication of Extract of Financial Results for the quarter and year ending 31st March, 2025
-
Board Meeting Outcome for Outcome Of Board Meeting
1d - Kilitch Drugs reports audited FY25 results with revenue Rs 19,530L and net profit Rs 3,116L standalone.
-
Financial Results
1d - Kilitch Drugs reports audited Q4 and FY25 financials with strong revenue and profit growth, unmodified audit opinion.
-
Board Meeting Intimation for Considering And Approving Standalone And Consolidated Quarterly Financial Results For The Period Ended 31St March, 2025
13 May - Board meeting on 19 May 2025 to approve FY25 audited financial results; trading window closed from 1 April 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Certificate received from MUFG Intime India Private Limited, the RTA of the Company
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Jun 2024TranscriptPPT
-
Jun 2023TranscriptPPT
Business Overview:[1]
KDL is a pharmaceutical company engaged in developing, manufacturing, marketing, and exporting various Pharmaceutical Formulations in dosage forms like Solid, Liquid, and Parental.